Hepatology 101 for Associates: Abnormal LFTs, Management of Portal Hypertension and Liver Lesions
Liver Diseases and
Transplantation Track
Friday, May 21, 1–2:30 p.m.
This session will cover how to approach and interpret abnormal liver tests, manage
complications of portal hypertension and when to appropriately refer for liver
transplantation and review imaging characteristics of benign and malignant hepatic
lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data
System for imaging findings in liver lesions.
Risk Stratification and Treatment of Liver Fibrosis
Liver Diseases and
Transplantation Track
Friday, May 21, 5:30–7 p.m.
The global burden of liver fibrosis is rising and has mainly been caused by the
consequences of obesity, diabetes and alcohol. Liver fibrosis often progresses to
cirrhosis and is responsible for liver- related mortality. Recent advances in the field
have resulted not only in utilizing novel diagnostic tools to allow risk stratification
of patients with liver fibrosis but also in identification of novel targets for
antifibrotic drug therapy.
What’s New, What’s Hot in Liver Transplantation?
Liver Diseases and
Transplantation Track
Saturday, May 22, 3:30–5 p.m.
This symposium, sponsored and organized by AASLD, covers
What’s New, What’s Hot in Liver Transplantation. Experts in the field will
discuss the latest developments in liver transplantation, including expanding
indications for both benign and malignant liver diseases. An update will also be
provided on the recent experience of successful utilization of liver grafts from
nonstandard donors and the research on perfusion machines.
COVID-19 and the Liver: Essential Updates for the GI and Hepatologist
Liver Diseases and
Transplantation Track
Sunday, May 23, 1-2:30 p.m.
This session will review outcomes of COVID-19 disease in patients with chronic liver
disease and cirrhosis as well as treatment of COVID-19 disease with underlying CLD. The
session will also discuss treatment of the underlying liver disease as well as
vaccination in this patient population.
Management of Drug-Induced Liver Injury
Liver Diseases and
Transplantation Track
Sunday, May 23, 1–2:30 p.m.
This program aims to address key concepts on the topic of drug induced liver injury
(DILI). These include making an accurate diagnosis, reviewing new and potential
treatments, genetic predisposition and immune mediated injury and clarifying the role of
liver transplantation in DILI.
Management of HBV in the Young Population
Liver Diseases and
Transplantation Track
Sunday, May 23, 1–2:30 p.m.
Chronic hepatitis B remains a “confusing” virus to understand and a challenge to manage,
especially in the young population who often present with their unique situations.
Therefore, this clinical symposium will focus on three common scenarios involving this
population in routine GI practice:
-
The young immune tolerant patient: how to evaluate and who to treat
-
The pregnant patient: how to monitor and who should be initiated on antivirals
-
The IBD patient who may have past or current chronic hepatitis B infection, who may
need prophylactic antivirals: for how long and how to monitor
Participants will learn from both focused didactic lectures as well as case studies with
take-home clinical “pearls” for daily practice.
Early Alcohol-Associated Liver Disease Spectrum: Screening and Diagnosis
Liver Diseases and
Transplantation Track
Sunday, May 23, 3:30–5 p.m.
Alcohol-associated liver disease (ALD) is the commonest etiology of liver disease
worldwide. Compared to non-alcoholic fatty liver disease and hepatitis C, ALD often
presents with an advanced spectrum of cirrhosis and complications. There remain clinical
unmet needs on strategies for screening the at-risk population with an aim for diagnosis
at an early stage, reducing the health care burden and improving the prognosis of
ALD.
Chronic HCV Infection in 2020: What Does the Future Hold?
Liver Diseases and
Transplantation Track
Sunday, May 23, 5:30–7 p.m.
Hepatitis C (HCV) continues to be a global cause of liver-related morbidity and
mortality, yet elimination is attainable. The World Health Organization has tasked
providers across the globe to achieve HCV elimination by 2030. The U.S. is far from this
trajectory. This HCV SIG program will address the changing demographics of HCV infection
and the evolution and barriers of the HCV care cascade as we strive to achieve
elimination targets.